Status: Recruiting
A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
This study intends to assess safety, tolerability, and efficacy of SENS-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the Otoferlin gene.
Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 6-31Biological sex: AllType: InterventionalSponsor: SensorionUpdated: Sep 26, 2024Locations: 2
Eligibility criteria
Children (male or female) ≥ 6 to ≤ 31 months at the time of inclusion [+5]
History of chronic, acute, or major disease, or unspecified reasons, that in the... [+6]